S&P 500   3,301.15 (+0.92%)
DOW   26,592.13 (+0.27%)
QQQ   276.03 (+1.62%)
AAPL   114.93 (+3.35%)
MSFT   204.68 (+0.99%)
FB   281.80 (+5.28%)
GOOGL   1,558.60 (+3.16%)
AMZN   3,208.13 (+1.43%)
TSLA   413.18 (+1.76%)
NVDA   521.95 (+3.34%)
BABA   309.19 (+0.41%)
CGC   18.35 (+0.05%)
GE   7.42 (+0.00%)
MU   50.34 (+0.68%)
AMD   78.16 (+2.30%)
T   26.80 (+1.13%)
F   7.97 (+3.51%)
ACB   3.85 (+0.52%)
GILD   57.72 (-1.70%)
NFLX   481.57 (-0.96%)
NIO   30.41 (+10.54%)
BA   148.07 (-0.05%)
DIS   120.31 (+1.55%)
S&P 500   3,301.15 (+0.92%)
DOW   26,592.13 (+0.27%)
QQQ   276.03 (+1.62%)
AAPL   114.93 (+3.35%)
MSFT   204.68 (+0.99%)
FB   281.80 (+5.28%)
GOOGL   1,558.60 (+3.16%)
AMZN   3,208.13 (+1.43%)
TSLA   413.18 (+1.76%)
NVDA   521.95 (+3.34%)
BABA   309.19 (+0.41%)
CGC   18.35 (+0.05%)
GE   7.42 (+0.00%)
MU   50.34 (+0.68%)
AMD   78.16 (+2.30%)
T   26.80 (+1.13%)
F   7.97 (+3.51%)
ACB   3.85 (+0.52%)
GILD   57.72 (-1.70%)
NFLX   481.57 (-0.96%)
NIO   30.41 (+10.54%)
BA   148.07 (-0.05%)
DIS   120.31 (+1.55%)
S&P 500   3,301.15 (+0.92%)
DOW   26,592.13 (+0.27%)
QQQ   276.03 (+1.62%)
AAPL   114.93 (+3.35%)
MSFT   204.68 (+0.99%)
FB   281.80 (+5.28%)
GOOGL   1,558.60 (+3.16%)
AMZN   3,208.13 (+1.43%)
TSLA   413.18 (+1.76%)
NVDA   521.95 (+3.34%)
BABA   309.19 (+0.41%)
CGC   18.35 (+0.05%)
GE   7.42 (+0.00%)
MU   50.34 (+0.68%)
AMD   78.16 (+2.30%)
T   26.80 (+1.13%)
F   7.97 (+3.51%)
ACB   3.85 (+0.52%)
GILD   57.72 (-1.70%)
NFLX   481.57 (-0.96%)
NIO   30.41 (+10.54%)
BA   148.07 (-0.05%)
DIS   120.31 (+1.55%)
S&P 500   3,301.15 (+0.92%)
DOW   26,592.13 (+0.27%)
QQQ   276.03 (+1.62%)
AAPL   114.93 (+3.35%)
MSFT   204.68 (+0.99%)
FB   281.80 (+5.28%)
GOOGL   1,558.60 (+3.16%)
AMZN   3,208.13 (+1.43%)
TSLA   413.18 (+1.76%)
NVDA   521.95 (+3.34%)
BABA   309.19 (+0.41%)
CGC   18.35 (+0.05%)
GE   7.42 (+0.00%)
MU   50.34 (+0.68%)
AMD   78.16 (+2.30%)
T   26.80 (+1.13%)
F   7.97 (+3.51%)
ACB   3.85 (+0.52%)
GILD   57.72 (-1.70%)
NFLX   481.57 (-0.96%)
NIO   30.41 (+10.54%)
BA   148.07 (-0.05%)
DIS   120.31 (+1.55%)
Log in
NYSE:CVM

CEL-SCI Stock Forecast, Price & News

$12.34
+0.01 (+0.08 %)
(As of 10/29/2020 12:43 PM ET)
Add
Compare
Today's Range
$11.90
Now: $12.34
$12.36
50-Day Range N/A
52-Week Range
$6.35
Now: $12.34
$18.00
Volume6,597 shs
Average Volume786,526 shs
Market Capitalization$476.62 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.13 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone703-506-9460
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$460,000.00
Book Value$0.15 per share

Profitability

Net Income$-22,140,000.00
Net Margins-4,864.64%

Miscellaneous

Market Cap$476.62 million
Next Earnings DateN/A
OptionableOptionable
$12.34
+0.01 (+0.08 %)
(As of 10/29/2020 12:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CEL-SCI (NYSE:CVM) Frequently Asked Questions

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSE:CVM) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.12. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.10 million. CEL-SCI had a negative net margin of 4,864.64% and a negative return on equity of 268.51%.
View CEL-SCI's earnings history
.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI's stock reverse split before market open on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are some of CEL-SCI's key competitors?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 61, Pay $607.02k)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 69, Pay $295k)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 64, Pay $376.39k)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 79, Pay $249.58k)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 78, Pay $202.68k)

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVM."

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $12.14.

How big of a company is CEL-SCI?

CEL-SCI has a market capitalization of $468.90 million and generates $460,000.00 in revenue each year. The company earns $-22,140,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

What is CEL-SCI's official website?

The official website for CEL-SCI is cel-sci.com.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 BOONE BLVD. SUITE 802, VIENNA VA, 22182. The company can be reached via phone at 703-506-9460 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.